The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GBIO | -62.5% | -98.68% | -57.89% | -98% |
| S&P | +13% | +86.41% | +13.26% | +122% |
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.59M | -78.9% |
| Gross Profit | $0.19M | -97.0% |
| Gross Margin | 11.92% | -72.5% |
| Market Cap | $41.22M | -75.0% |
| Market Cap / Employee | $0.36M | 0.0% |
| Employees | 115 | -33.9% |
| Net Income | -$5.52M | 64.0% |
| EBITDA | -$20.09M | -29.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $21.94M | 1.3% |
| Accounts Receivable | $0.39M | -82.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $19.74M | -76.2% |
| Short Term Debt | $6.35M | -41.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -33.79% | 12.4% |
| Return On Invested Capital | -43.30% | 56.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$52.68M | -168.3% |
| Operating Free Cash Flow | -$52.68M | -169.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.82 | 0.37 | 0.40 | 0.76 | -51.75% |
| Price to Sales | 3.56 | 1.11 | 1.01 | 2.70 | -69.57% |
| Price to Tangible Book Value | 6.77 | 3.15 | 2.92 | 0.76 | -94.66% |
| Enterprise Value to EBITDA | 1.14 | 3.12 | 1.63 | 1.11 | -123.35% |
| Return on Equity | -91.0% | -70.1% | -85.4% | -80.8% | -6.58% |
| Total Debt | $93.56M | $87.58M | $85.32M | $26.10M | -72.17% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
